10761751

Source:http://linkedlifedata.com/resource/pubmed/id/10761751

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0015730, umls-concept:C0040808, umls-concept:C0205195, umls-concept:C0677850, umls-concept:C0746319, umls-concept:C1705294
pubmed:issue	2
pubmed:dateCreated	2000-6-21
pubmed:abstractText	Docetaxel is an active agent in the treatment of metastatic breast cancer. We evaluated the feasibility of docetaxel-based sequential and combination regimens as adjuvant therapies for patients with node-positive breast cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0923-7534
pubmed:author	pubmed-author:BartholomeusSS, pubmed-author:CroweSS, pubmed-author:Di LeoAA, pubmed-author:DolciSS, pubmed-author:DuffyKK, pubmed-author:LarsimontDD, pubmed-author:NogaretJ MJM, pubmed-author:O'HigginsNN, pubmed-author:PaesmansMM, pubmed-author:PiccartM JMJ, pubmed-author:RivaAA, pubmed-author:RowanSS
pubmed:issnType	Print
pubmed:volume	11
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	169-75
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:10761751-Adult, pubmed-meshheading:10761751-Aged, pubmed-meshheading:10761751-Antineoplastic Agents, Phytogenic, pubmed-meshheading:10761751-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10761751-Breast Neoplasms, pubmed-meshheading:10761751-Chemotherapy, Adjuvant, pubmed-meshheading:10761751-Confidence Intervals, pubmed-meshheading:10761751-Cyclophosphamide, pubmed-meshheading:10761751-Dose-Response Relationship, Drug, pubmed-meshheading:10761751-Doxorubicin, pubmed-meshheading:10761751-Drug Administration Schedule, pubmed-meshheading:10761751-Feasibility Studies, pubmed-meshheading:10761751-Female, pubmed-meshheading:10761751-Fluorouracil, pubmed-meshheading:10761751-Follow-Up Studies, pubmed-meshheading:10761751-Humans, pubmed-meshheading:10761751-Lymphatic Metastasis, pubmed-meshheading:10761751-Methotrexate, pubmed-meshheading:10761751-Middle Aged, pubmed-meshheading:10761751-Neoplasm Staging, pubmed-meshheading:10761751-Paclitaxel, pubmed-meshheading:10761751-Survival Rate, pubmed-meshheading:10761751-Taxoids, pubmed-meshheading:10761751-Treatment Outcome
pubmed:year	2000
pubmed:articleTitle	A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
pubmed:affiliation	Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium. Angelo.Dileo@swing.be
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Multicenter Study